given confidential treatment. However, should any of these records come into the possession of the Federal Reserve, such information may be protected from disclosure by exemption 4 and 6 of the Freedom of Information Act (5 U.S.C. 552(b)(4) and (b)(6)).

Abstract: Regulation H requires state member banks to notify a borrower and servicer when loans secured by real estate are determined to be in a special flood hazard area and notify them whether flood insurance is available; notify FEMA of the identity of, and any change of, the servicer of a loan secured by real estate in a special flood hazard area; and retain a completed copy of the Standard Flood Hazard Determination Form used to determine whether property securing a loan is in a special flood hazard area.

Board of Governors of the Federal Reserve System, September 27, 2002.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 02–25036 Filed 10–1–02; 8:45 pm]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisition of Shares of Bank or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. The notices also will be available for inspection at the office of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than October 16, 2002.

A. Federal Reserve Bank of Atlanta (Sue Costello, Vice President) 1000 Peachtree Street, N.E., Atlanta, Georgia 30309–4470:

1. Joseph Bienvue Falgoust, Vacherie, Louisiana; Charles J. Falgoust, Vacherie, Louisiana; Dean T. Falgoust, River Ridge, Louisiana; Marian A. Falgoust, Metairie, Louisiana; Michael A. Falgoust, Vacherie, Louisiana; Ronald J. Falgoust, Thibodaux, Louisiana; Rose Mary Falgoust, Vacherie, Louisiana; Susan B. Falgoust, Vacherie, Louisiana; Falgoust Family Holdings, LLC, Vacherie, Louisiana; Blake J. Falgoust, Vacherie, Louisiana; Ronald A. Ordoyne, Vacherie, Louisiana; Joan Ordoyne, as custodian for Luke Falgoust; Vacherie, Louisiana; Joan Ordoyne, as custodian for Laura Falgoust, Vacherie, Louisiana; Francois P. Falgoust, Vacherie, Louisiana; Ulger Landry, Vacherie, Louisiana; and Denny Guillot, Raceland, Louisiana; to acquire additional voting shares of One American Corp., and thereby indirectly acquire additional voting shares of First American Bank and Trust, both of Vacherie, Louisiana.

Board of Governors of the Federal Reserve System, September 26, 2002.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 02–25040 Filed 10–1–02; 8:45 am]

BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Consumer Advisory Council

ACTION: Notice of Meeting of Consumer Advisory Council

SUMMARY: The Consumer Advisory Council will meet on Thursday, October 24, 2002. The meeting, which will be open to public observation, will take place at the Federal Reserve Board's offices in Washington, DC, in Dining Room E on the Terrace level of the Martin Building. Anyone planning to attend the meeting should, for security purposes, register no later than Tuesday, October 22, by completing the form found on–line at: *http://www.federalreserve.gov/forms/cacregistration.cfm*. Additionally, attendees must present photo identification to enter the building.

The meeting will begin at 9:00 a.m. and is expected to conclude at 1:00 p.m. The Martin Building is located on C Street, NW, between 20th and 21st Streets.

The Council's function is to advise the Board on the exercise of the Board's responsibilities under various consumer financial services laws and on other matters on which the Board seeks its advice. Time permitting, the Council will discuss the following topics:

Real Estate Settlement Procedures Act: Discussion of aspects of the proposed revisions by the Department of Housing and Urban Development to the rules implementing the Real Estate Settlement Procedures Act.

Identify Theft: Discussion of deterrence options for identify theft.

Access to Credit Cards: Discussion of access to credit by consumers who may not have the ability to repay, particularly students.

Committee Reports: Council committees will report on their work.

Other matters initiated by Council members also may be discussed.

ADDRESSES: Persons wishing to submit views to the Council on any of the above topics may do so by sending written statements to Ann Bistay, Secretary of the Consumer Advisory Council, Division of Consumer and Community Affairs, Board of Governors of the Federal Reserve System, Washington, DC 20551. Information about this meeting may be obtained from Ms. Bistay, 202–452–6470.

Board of Governors of the Federal Reserve System, September 26, 2002.

Jennifer J. Johnson,

Secretary of the Board.

[FR Doc. 02–25038 Filed 10–1–02; 8:45 am]

BILLING CODE 6210–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Resources and Services Administration

Ricky Ray Hemophilia Relief Fund Program Procedure for Augmenting Petitions and Reminder of Termination Date of Fund

AGENCY: Health Resources and Services Administration, HHS.

ACTION: Notice.

SUMMARY: The purpose of this notice is to announce the procedure for the augmentation of petitions filed with the Ricky Ray Hemophilia Relief Fund Program, postmarked by the November 13, 2001, statutory deadline, for which an initial payment decision has been made; and to remind the public of the November 12, 2003, termination date of the Ricky Ray Hemophilia Relief Fund.

DATES: The termination date of the Ricky Ray Trust Fund is November 12, 2003.

ADDRESSES: All documentation to augment eligible petitions must be submitted to the Ricky Ray Program, Bureau of Health Professions, Health Resources and Services Administration, Room 4–81, Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

FOR FURTHER INFORMATION CONTACT: Paul T. Clark, Director, Ricky Ray Program, Bureau of Health Professions, Health Resources and Services Administration, (301) 443–2330.

SUPPLEMENTARY INFORMATION: The order of the review and payment decision of

any specific petition filed with the Ricky Ray Program was based on the postmark date of the petition. The facts related to the petition may have changed over time subsequent to the payment decision. This document addresses how the Ricky Ray Program will handle new information that becomes available before the Ricky Ray Trust Fund terminates on November 12, 2003, where the new information may change the payment decision of a petition that has been approved for a payment of less than $100,000, or a disapproved petition.

This document also reminds the public of the termination date of the Ricky Ray Hemophilia Relief Fund, November 12, 2003. This date is governed by section 101(d) of the Act, which states that the Fund shall terminate upon the expiration of the 5-year period beginning on the date of enactment of the Act on November 12, 1998. The unobligated funds remaining at the end of this period shall be deposited in the miscellaneous receipts account in the Treasury of the United States.

Background

The Ricky Ray Program implements the Ricky Ray Hemophilia Relief Fund Act of 1998 (the Act), Pub. Law 105–369. The Act provides for compassionate payments to individuals with blood-clotting disorders, such as hemophilia, who were treated with antihemophilic factor between July 1, 1982 and December 31, 1987, and contracted human immunodeficiency virus (HIV), as well as to certain persons who contracted HIV from these individuals. In the event individuals eligible for payment are deceased, the Act also provides for payments to certain survivors of these individuals.

Petition payment determinations under the Act are based upon the documents that were included in a petition as of the date the petition was reviewed. As a result, some petitions were approved for a payment of less than $100,000 or were disapproved because the documentation submitted with the petition did not support a payment of $100,000.

The Act stipulates that petitions are to be reviewed in the order received. To comply with this legislative mandate, the Ricky Ray Program developed and implemented its petition review process whereby petitions would be randomly numbered by the postmark date and reviewed in accordance with the randomly assigned number. The Program also decided to make payments as soon as possible after all July 31, 2000, postmarked petitions were in-house, rather than waiting until after the filing deadline date, November 13, 2001, to begin making payments. These decisions addressed a series of Program-related factors such as: the mortality of the target population, the initial amount of $75 million appropriated for the Program in fiscal year 2000, and the uncertainty of future appropriations.

The Act and its regulations recognize that petitions may be affected by circumstances beyond petitioners' control that could impact a payment decision. Section 130.24 (a) of the Ricky Ray Program's Final Rule with Amendments (66 FR 58667) states that where a petition raises an eligibility or payment question, ''the Secretary may require the petitioner to provide other documentation, as the Secretary deems appropriate, to resolve issues of eligibility, or of the procedure for payment, raised by a petition.'' This regulatory provision allows a petitioner to augment a petition with new documents or additional information from any source provided that the petition was postmarked on or before November 13, 2001. The Act and its regulations also provide for a two-year period between the final postmark date and the date when the Program's Trust Fund terminates. This authority permits the Secretary to review the most recent documentation available to resolve any eligibility or payment issue relating to an approval or disapproval decision on a petition.

The Ricky Ray Program, by statute, is authorized to pay $100,000 on behalf of an eligible individual with HIV. In the case of multiple survivors, *i.e.*, children or parents, the $100,000 payment must be divided in equal shares among that class of survivors. There are petitioner survivors whose petitions only included documentation that supported their portion of the payment of $100,000.

Criteria for Augmentation

The following criteria must be met in order for a petition to be eligible for augmentation.

1. Only a petition postmarked by November 13, 2001, and, therefore, included in the Ricky Ray Program system of records, may be augmented.

The Ricky Ray Program regulations stipulate that petitions submitted to the Program must be postmarked between July 31, 2000, and November 13, 2001. Petitions postmarked during this period of time were given a petition number and recorded in the Program's system of records.

2. Only a petitioner, a petitioner's personal representative, or a disinterested third party, such as a court, a hospital, or a state department of vital statistics, may augment a petition.

A petitioner, a petitioner's personal representative, or a disinterested third party may augment a petition with documentation that could affect the Program's petition payment decision. The documentation or information that augments the petition must be received by the Program in sufficient time before November 12, 2003, to allow for review and processing before the Fund terminates.

In implementing this procedure with regard to payment decisions for survivors of eligible individuals, the Ricky Ray Program will make payments in accordance with section 103(c)(2)(A) of the Act, which establishes a hierarchy of survivors, as follows:

1. Surviving spouse.

2. Child(ren) in equal shares if there is no surviving spouse.

3. Parent(s) in equal shares if there are no surviving spouse or surviving children.

Documentation Required for Augmentation

The documentation or information that the Program may consider when a petitioner, petitioner's personal representative, or the disinterested third party augments a petition includes, but is not limited to:

1. A court order determining that the other surviving parent's parental rights have been terminated.

2. A death certificate of the other eligible survivor(s).

3. Other evidence establishing eligibility for the full payment, such as: (a) An order from a court of competent jurisdiction documenting that the survivor is the sole survivor of the eligible individual; (b) documentation that supports the existence of a relationship between a survivor and an eligible individual, which may, in some circumstances, include Social Security, Department of Veterans Affairs or Department of Defense benefits to survivors; (c) documentation that the medical requirements necessary for eligibility have been met.

Any documentation submitted by a petitioner, a petitioner's personal representative, or a disinterested third party to augment a petition must be received by the Ricky Ray Program in sufficient time to allow for processing and payment prior to the Trust Fund's termination date of November 12, 2003. No payments will be made after that date.

Examples of how this augmentation procedure will be implemented are available on the Ricky Ray Program

website at: *http://www.hrsa.gov/bhpr/rickyray.*

Paperwork Reduction Act

The information collection requirements for the Ricky Ray Homphilia Relief Fund (42 CFR part 130) have been approved under OMB No. 0915–0244.

Dated: September 24, 2002.

Elizabeth M. Duke,

Administrator.

[FR Doc. 02–24953 Filed 10–1–02; 8:45 am]

BILLING CODE 4165–15–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Scientific Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) and the Assistant Secretary for Health have taken final action in the following case:

Heather J. Muenchen, Ph.D., University of Michigan: Based on the report of an investigation conducted by the University of Michigan (UM), Dr. Muenchen's admissions, and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Dr. Muenchen, former postdoctoral fellow at UM, engaged in scientific misconduct in research funded by National Institutes of Health (NIH) Urology Research Training Grant T32 DK07758 and SPORE grant PSO CA69568. Dr. Muenchen falsified and fabricated research data by computer manipulation of 12 Western blot analyses in three publications and two draft manuscripts.

Specifically, PHS found that Dr. Muenchen:

(1) Falsified Western blot data in Figures 3, 4A, and 4B in the following paper: Muenchen, H.J., Lin, D–L., Walsh, M.A., Keller, E.T., and Pienta, K.J. ''Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-κB by an IκBα 'super-repressor.' '' Clinical Cancer Research 6(5):1969–1977, 2000;

(2) Falsified Western blot data in Figures 2 and 3 in the following paper: Muenchen, H.J., Poncza, P.J., and Pienta, K.J. ''Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC–3.'' Urology 57(2):366–370, 2001;

(3) Falsified Western blots and associated claims for Figures 1, 5A, 5B, and 8 in the following paper: Muenchen, H.J., Lin, D–L., Poncza, P.J., McLean, L.L, Dirette, M.L., Keller, E.T., and Pienta, K.J. ''Re-expression of functional androgen receptor in androgen-independent prostate cancer cells.'' Published electronically on November 13, 2000 in the Journal of Biological Chemistry (JBC) as Online Manuscript M008934200 (withdrawn January 16, 2001); and

(4) Falsified Western blot analyses in Figures 4A, 4B, and 7 of the original draft submitted for publication on September 29, 2000, (and the corresponding Figures 5A, 5B, and 8 in the second draft submitted October 20, 2000) of the JBC manuscript.

Dr. Muenchen was the first and corresponding author on the above publications, which were supported in part by Urology Research Training Grant T32 DK07758 and SPORE grant P50 CA69568. These falsifications are significant because they misrepresent the expression of the androgen receptor, the necessary control data, the evidence for ''super-repressor'' binding and its effect, and the control data for assaying apoptosis. These misrepresentations occurred through a series of separate and specific deceptions in an attempt to obviate the legitimate criticisms of publication reviewers. These falsifications were designed to be misleading about the experiments' true results and to wrongfully induce publication of the experiments. Dr. Muenchen's work could have provided tools for understanding metastasis in prostate cancer and ultimately impact on treatment of this disease.

Dr. Muenchen has entered into a Voluntary Exclusion Agreement in which she has voluntarily agreed:

(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility for, or involvement in, nonprocurement transactions (*e.g.*, grants and cooperative agreements) of the United States Government as defined in 45 CFR part 76 (Debarment Regulations) for a period of five (5) years, beginning on September 5, 2002;

(2) To exclude herself from serving in any advisory capacity to PHS including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant for a period of five (5) years, beginning on September 5, 2002; and

(3) Within 30 days of the effective date of this Agreement, to submit letters of retraction to the editor of Urology retracting the paper published at 57(2):366–370, 2001, and to the editor of Clinical Cancer Research, published at 6(5):1969–1977, 2000, identifying and retracting the falsified or fabricated data in Figure 3 and Figures 4A and 4B. The retraction requirements will remain on the ALERT System until Dr. Muenchen sends, and ORI receives, copies of the retraction letters consistent with the above language.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 5515 Security Lane, Suite 700, Rockville, MD 20852, (301) 443–5330.

Chris B. Pascal,

Director, Office of Research Integrity.

[FR Doc. 02–24952 Filed 10–1–02; 8:45 am]

BILLING CODE 4150–31–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[Program Announcement 02185]

Cooperative Agreement to the Association of Immunization Managers; Notice of Award of Funds

A. Purpose

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2002 funds for a cooperative agreement program for the Association of Immunization Managers. This program addresses the ''Healthy People 2010'' focus area of Immunization and Infectious Diseases.

The purpose of the program is to (1) maintain an effective communication capacity among the nation's immunization program managers and CDC; (2) sustain a capacity to coordinate both rapid and comprehensive assessments of problems and opportunities faced by immunization managers; and (3) establish a capacity to coordinate the consultations and collaborations that will enable state and local health departments to assimilate and implement the latest programmatic, scientific and technological developments and concepts affecting the goal of immunizing our nation's citizens.

B. Eligible Applicants

Assistance will be provided only to the Association of Immunization Mangers (AIM). No other applications are solicited. AIM is the only organization that has an established relationship with state and local health department immunization programs, access to public health managers and